 |
Registered Charity No. 1060134 |
CME Course |
Uremic Toxins and
Cardiovascular Disease
(3rd meeting)
The Cathedral, Amiens, France
October 3 - 5, 2008 |
Amiens South University Hospital (CHU Amiens Sud) |
Amiens, France |
ERA-EDTA
European Council for Accreditation in CME in Nephrology, Dialysis and Transplantation (ECANDT of the ERA-EDTA accredited by the European Accreditation Council
for CME - EACCME).
ERA-EDTA European Council for Accreditation in CME in Nephrology, Dialysis and Transplantation (ECANDT of the ERA-EDTA accredited by the European Accreditation Council for CME - EACCME). |
Chair-person: R. Coppo (Italy) |
Secretary: A.L.M. De Francisco (Spain) |
Members: J. Floege (Germany) |
R. Vanholder (Belgium) |
A. Wiecek (Poland) |
C. Zoccali (Italy) |
G.M. London, ERA-EDTA President (France) |
CME Courses Coordinators: |
Basic Science and Clinical Nephrology: R. Coppo (Italy) and P. Ronco (France).
|
Chronic Renal Failure, Hypertension and Clinical Epidemiology: C. Zoccali (Italy) and G. London (France). |
Dialysis: R. Vanholder (Belgium), S. Davies (UK) and C. Wanner (Germany). |
Transplantation: C. Ponticelli (Italy) and J. Grinyo (Spain). |
Collaboration with ISN for courses in Eastern Europe: N. Lameire (Belgium), A. Covic (Romania). |
Congress President : Ziad Massy
Chairman of EUTox group : Raymond Vanholder
Deadline for abstracts submission: June 1, 2008 |
Deadline for abstracts confirmation: July 15, 2008 |
Deadline for early registration : September 1, 2008 |
Deadline for reserving accomodation : August 1, 2008 |
Official congress agency: |
| SagaCom |
Official Website: http://www.eutox-cvd.fr |
Main topics: |
|
1) CVD in CKD Epidemiological data
|
2) Uremic toxins (basic science)
|
3) Classical risk factors (lipids, blood pressure, diabetes) |
4) Non-classical risk factors (vascular calcifications, calcium-phosphorus abnormalities, bone markers) |
5) Non-classical risk factors (anemia, oxidative stress, inflammation, nutrition)
|
6) Non-classical risk factors (endothelial dysfunction, vascular stiffness, microalbuminuria/proteinuria) |
7) New omic approaches |
8) Therapeutic strategies (new dialysis procedures, transplantation, pharmacological approaches) |
COURSE PROGRAMME |
|
Day 1 - Friday 3rd of October |
|
12:00-13:30 |
Welcome buffet |
13:30-14:15 |
General introduction and welcome |
Chairman: Z Massy, R Vanholder |
|
Z Massy (President of the Congress) |
|
R Vanholder (President of EUTox Group) |
|
B Nemitz (Dean of Medical School) |
|
M Brazier (Dean of Pharmacy School) |
|
14:15-15:00 |
CVD in CKD Epidemiological data |
| Chairman: C Baigent, A Fournier |
|
14:15-14:35
|
M Tonelli: Epidemiology of cardiovascular disease (CVD) in CKD - the renocardiac link |
14:35-14:55 |
K Jager: How epidemiological research can help to overcome the epidemic of renocardiac disease |
14:55-15:00 |
1 oral presentation [5 minutes] |
15:00-15:30 |
Break |
15:30-17:00 |
CVD in CKD Classical risk factors |
| Chairman: A Covic, A Wiecek |
|
15:30-15:50 |
DC Wheeler: New insights on lipids and CVD in CKD |
15:50-16:10 |
C Zoccali: New insights on blood pressure and CVD in CKD |
16:10-16:30 |
V Tesar: New insights on diabetes and CVD in CKD |
16:30-16:50 |
M Landray: What is the predictive value of classical CV risk factors in CKD? |
16:50-17:00 |
2 oral presentations [5 minutes per presentation] |
19:00 |
Speakers/International committee dinner |
Day 2 - Saturday 4th of October |
|
08:30-09:45 |
CVD in CKD Uremic toxins |
Chairman: Ph Brunet, R Vanholder |
|
8:30-8:50 |
A Perna: New insights on homocysteine toxicity |
8:50-9:10 |
P Thornalley: Hotspots and highlights of AGE formation in uremia and risk of CVD |
9:10-9:30 |
G Glorieux: New insights in the toxicity of protein bound molecules |
9:30-9:45 |
3 oral presentations [5 minutes per presentation] |
9:45-11:00 |
Break and poster session |
11:00-12:30 |
CVD in CKD Non-classical risk factors (I) |
Chairman: E Ritz, TB Drüeke |
|
11:00-11:10 |
E Ritz: Introduction |
11:10-11:30 |
Z Massy: Vascular calcification and CVD in CKD |
11:30-11:50 |
M Ketteler: Vitamin D and CVD in CKD |
11:50-12:10 |
M Rodriguez-Portillo: Calcium-phosphorus-PTH abnormalities and CVD in CKD |
12:10-12:30 |
M Nishisawa: Are bone-related markers significant factors for CVD in hemodialysis patients? |
12:30-13:30 |
Lunch |
13:30-14:45 |
CVD in CKD: New omic approaches |
Chairman: A Argiles, P Brouckaert |
|
13:30-13:50 |
G Navis: Genomic research and CVD in CKD |
13:50-14:10 |
H Mischak: Proteomic research and CKD |
14:10-14:30 |
J Jankowski: Metabolomic research and CKD |
14:30-14:45 |
3 oral presentations [5 minutes per presentation] |
14:45-16:00 |
Break and poster session |
16:00-18:00 |
CVD in CKD: Non-classical risk factors (II) |
Chairman: G Kaysen, G Choukroun |
|
16:00-16:20 |
TB Drüeke: Anemia and CVD in CKD |
16:20-16:50 |
T Nakanishi: Iron and CVD in CKD: Unveiling the silent killer? |
16:50-17:10 |
J Himmelfarb: Oxidative stress and CVD in CKD |
17:10-17:30 |
P Stenvinkel: Inflammation and CVD in CKD |
17:30-17:50 |
D Fouque: Protein-Energy wasting in CKD: risk factor for increased cardiovascular |
17:50-18:00 |
2 oral presentations [5 minutes per presentation] |
19:30 |
Gala dinner |
Day 3 - Sunday 5th of October |
|
8:30-10:15 |
CVD in CKD Non-classical risk factors (III) |
Chairman: S Herget-Rosenthal, F Locatelli |
|
8:30-8:50 |
D Fliser: ADMA and CVD in CKD |
8:50-9:10 |
AJ van Zonneveld: Endothelial progenitor cells and CVD in CKD |
9:10-9:30 |
G London: Arterial stiffness and CVD in CKD |
9:30-9:50 |
D de Zeeuw: Microalbuminuria/proteinuria and CVD in CKD |
9:50-10:10 |
G Tsirpanlis: Cellular senescence, CVD, and CKD |
10:10-10:15 |
1 oral presentation [5 minutes] |
10:15-10:45 |
Break |
10:45-12:30 |
CVD in CKD Therapeutic strategies |
Chairman: M Jadoul, G Spasovski |
|
10:45-11:05 |
B Canaud: New hemodialysis procedures –HDF to reduce CVD in CKD |
11:05-11:25 |
W Van Biesen: Peritoneal dialysis to reduce CVD in CKD |
11:25-11:45 |
U Baurmeister: Removal strategies: can we make further progress? |
11:45-12:05 |
C Wanner: Pharmacological approaches to reduce CVD in CKD: what makes efficient treatment difficult? |
12:05-12:25 |
B Kasiske: Kidney transplantation and new immunosuppressive therapies to reduce CVD in CKD |
12:25-12:30 |
1 oral presentation [5 minutes] |
12:30-13:00 |
Concluding remarks: Z Massy, R Vanholder |
13:00-14-00 |
Lunch |